Black Diamond Therapeutics (BDTX) Cash from Operations: 2019-2021
Historic Cash from Operations for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2021 value amounting to -$24.0 million.
- Black Diamond Therapeutics' Cash from Operations fell 52.44% to -$24.0 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$100.1 million, marking a year-over-year decrease of 92.05%. This contributed to the annual value of -$62.3 million for FY2024, which is 6.62% up from last year.
- Black Diamond Therapeutics' Cash from Operations amounted to -$24.0 million in Q4 2021, which was up 9.20% from -$26.5 million recorded in Q3 2021.
- Black Diamond Therapeutics' Cash from Operations' 5-year high stood at -$5.0 million during Q2 2019, with a 5-year trough of -$26.5 million in Q3 2021.
- In the last 3 years, Black Diamond Therapeutics' Cash from Operations had a median value of -$12.5 million in 2020 and averaged -$14.7 million.
- Data for Black Diamond Therapeutics' Cash from Operations shows a maximum YoY slumped of 171.34% (in 2020) over the last 5 years.
- Black Diamond Therapeutics' Cash from Operations (Quarterly) stood at -$7.5 million in 2019, then slumped by 110.71% to -$15.8 million in 2020, then slumped by 52.44% to -$24.0 million in 2021.
- Its Cash from Operations stands at -$24.0 million for Q4 2021, versus -$26.5 million for Q3 2021 and -$25.2 million for Q2 2021.